孟鲁司特联合酮替芬对哮喘患者血清TGF-β1、MCP-1、SDF-1水平的影响

The impact of montelukast combined with Ketotifen on the levels of serum TGF-β_1,MCP-1,SDF-1 in asthma sufferers

目的观察孟鲁司特联合酮替芬对哮喘患者血清转化生长因子-β_1(TGF-β_1)、单核细胞趋化蛋白-1(MCP-1)、基质细胞衍生因子-1(SDF-1)水平的影响。方法 2014年10月—2015年10月南京医科大学附属无锡第二人民医院呼吸科收治哮喘患者128例,随机数字表法分为观察组及对照组各64例,2组患者均给予对症治疗,对照组同时给予孟鲁司特口服,观察组给予孟鲁司特联合酮替芬口服,治疗时间为3个月。观察2组患者治疗效果及治疗前后血清TGF-β_1、MCP-1、SDF-1水平的变化。结果观察组总有效率为96.9%,高于对照组的84.4%(P<0.05);治疗后,观察组哮喘控制测试表(ACT)评分为(24.25±3.98)分,显著高于对照组的(20.12±4.02)分(P<0.05);观察组第一秒呼气容积(FEV_1)和呼气峰值流速(PEF)分别为(80.25±4.25)%、(7.25±0.69)L/min,高于对照组的(75.02±3.96)%、(5.82±0.70)L/min(P<0.05);血清TGF-β_1、MCP-1、SDF-1水平分别为(42.2±6.0)ng/ml、(48.6±4.0)pg/ml、(252.4±32.2)ng/L,低于对照组的(48.9±5.2)ng/ml、(59.0±4.2)pg/ml、(425.3±40.6)ng/L,差异均有统计学意义(P<0.05)。结论孟鲁司特联合酮替芬能有效降低哮喘患者血清TGF-β_1、MCP-1、SDF-1水平,改善患者临床症状及肺功能,提高患者治疗效果。

Objective To investigate the impact of montelukast combined with Ketolifen on the levels of transforming growth factor-β1（TGF-β1）,monocyte chemoattractanl protein-1（MCP-1）,stromal cell derived factor-1（SDF-1） in asthma sufferers.Methods 128 cases of asthma patients in Department of Respiration,Wuxi Second People＇s Hospital Affiliated to Nanjing Medical University（nun October 2014 to October 2015 were selected and randomly divided into observation group（n =64） and control group（n =64）.Patients of two groups were given symptomatic treatment;patients of the observation group were treated with muntclukasl combined with Ketolifen orally,while patients of the control group were treated with monlelukasl orally,and both for three nionlhs.The levels of TGF-β1.MCP-1,SDF-1 of two groups before and after treatment were compared.Results The total effective rale of observation group（96.9%） were higher than control group（84.4%）（P〈0.05）.The Asthma Control Test table（ACT） score of observation group（24.25 ± 3.98） was significantly higher than control group（20.12 ±4.02）（P〈0.05）.The levels of expiratory volume in one second（FEV1） and peak expiratory flow rate（PEF） of observation group were（80.25 ± 4.25）%,（7.25 ± 0.69） L/min were higher than control group（75.02 ±3.96）%,（5.82 ±0.70） L/min（P〈0.05）.The levels of serum TGF-β1,MCP-1,SDF-1 of observation group（42.2 ±6.0） ng/ml,（48.6 ±4.0） pg/ml,（252.4 ±32.2） ng/L after treatment were lower than the control group（48.9 ±5.2）ng/ml,（59.0±4.2） pg/ml,（425.3±40.6） ng/L,the difference was statistically significant（P〈0.05）.Conclusion Monlelukasl combined with Kelotifen can effectively reduce scrum TGF-β1,MCP-1.SDF-1 levels in asthmatic patients and improve clinical symptoms,lung function and improve patient outcomes.